Ideas That Generate Results

Global Pneumonia Vaccine Market Outlook 2020

Global Pneumonia Vaccine Market Outlook 2020

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Jun, 2015| No. of Pages : 50

Share |
Please make your selection :
Electronic Access - Single User License
US$ 1500.00
CD-ROM Mail Delivery
US$ 1700.00
Hard Copy Mail Delivery
US$ 1700.00
Electronic Access - Multi-User License
US$ 2500.00

According to a new research, introduction of the 10-valent pneumococcal conjugate vaccine, PCV10, decreases the rates of clinical pneumonia even in unvaccinated children, a classic example of herd immunity. With a greater number of serotypes in current vaccines, there has been more disease reduction in both vaccinated and unvaccinated populations. As vaccines evolve, similar improvements can be expected.

According to our report, “Global Pneumonia Vaccine Market Outlook 2020”, the Pneumonia vaccine market for 2014, which has been estimated at US$ 5.9 Billion, is expected to reach US$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. The report offers a clear and succinct take on the current Pneumococcal Vaccine Industry. The current market and future forecasts for the industry have been derived. The regional distribution of the current market has also been discussed. It has been noted that although USA and Europe are the major shareholders in the market, the developing regions are expected to account for a significant share too. This shift can be attributed to the rising incidences as well as the increasing purchasing power of the populations in these regions. Government’s focus on a preventive healthcare strategy to cut down costs is also set to play a major role in the growth of the vaccine industry.

As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing.

Lastly, the report discusses the three major players in the industry viz., GlaxoSmithKline, Pfizer and Merck. The competitive landscape is supplemented with a chapter highlighting the current share of every player in the market. This is followed by company profiles, wherein the general business along with key financials of every player has been provided. At the end of every profile, a strength and weakness analysis has been performed. The report provides a prudent analysis of the market and is a must have supplement for any player interested in the industry.

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.